Popular filter options for chondrosarcoma trials
Soft Tissue Sarcoma Clinical Trials
View 7 Soft Tissue Sarcoma medical studies.
Virus Therapy
AdAPT-001 for Cancer
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
CAR T-cell Therapy
TIL Therapy for Cancer
This trial will test how well LN-145 or LN-145-S1 work in treating patients with ovarian cancer, triple negative breast cancer, anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment or that has come back.
Janus Kinase (JAK) Inhibitor
Itacitinib for Sarcomas
This trial looks at whether itacitinib can help treat patients with sarcomas that haven't responded to other treatments and have spread to other parts of the body. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
STS Clinical Trials
View 7 STS medical studies.
Virus Therapy
AdAPT-001 for Cancer
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
CAR T-cell Therapy
TIL Therapy for Cancer
This trial will test how well LN-145 or LN-145-S1 work in treating patients with ovarian cancer, triple negative breast cancer, anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment or that has come back.
Janus Kinase (JAK) Inhibitor
Itacitinib for Sarcomas
This trial looks at whether itacitinib can help treat patients with sarcomas that haven't responded to other treatments and have spread to other parts of the body. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Chondrosarcoma Clinical Trials With No Placebo
View 20 chondrosarcoma medical studies that do not have a placebo group.
Glutaminase Inhibitor
IACS-6274 +/− Bevacizumab/Paclitaxel for Cancer
This trial is testing a new drug to see if it's safe and effective in treating patients with advanced solid tumors. The new drug, IACS-6274, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IACS-6274 with or without pembrolizumab may help to control the disease.
Virus Therapy
AdAPT-001 for Cancer
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
Monoclonal Antibodies
INBRX-109 for Solid Tumors
This trial is testing a new drug, INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5). This is the first time this drug is being tested in humans. The trial has three parts.
View More Chondrosarcoma Trials
See another 3 medical studies focused on chondrosarcoma.
Frequently Asked Questions
Introduction to chondrosarcoma
What are the top hospitals conducting chondrosarcoma research?
In the realm of clinical trials targeting chondrosarcoma, several top hospitals have emerged as beacons of hope for patients. Among them is Memorial Sloan Kettering Cancer Center in New York, which currently leads the pack with six active trials focused on this rare form of bone cancer. Having recorded its first chondrosarcoma trial in 2018, Memorial Sloan Kettering's dedication to finding effective treatments is evident. MD Anderson Cancer Center in Houston joins the ranks with five ongoing chondrosarcoma trials and a history that dates back to their inaugural study in 2006. Not far behind is the Sarcoma Oncology Center located amidst sunny Santa Monica, California. This center boasts four active clinical trials for chondrosarcoma and began its journey towards combating this condition in 2007.
Houston's M D Anderson Cancer Center remains steadfastly committed to fighting against this malignancy as well, seeking innovative solutions through three current chondrosarcoma trials since recording their first investigation also around 2007.Boston's Massachusetts General Hospital rounds out this list by offering three active clinical studies regarding chondrosarcoma while having embarked on their exploration into this cancer type as early as1999.
Chondrosarcoma presents unique challenges due to its rarity and complexity; however, these leading hospitals' unwavering commitment showcases the progress being made in understanding and treating this disease. Collaborative efforts across institutions provide invaluable opportunities for patients affected by chondrosarcoma, inching closer towards improved outcomes and ultimately a brighter future for those diagnosed with this challenging condition
Which are the best cities for chondrosarcoma clinical trials?
When it comes to chondrosarcoma clinical trials, several cities emerge as prime hubs for research and development. Houston, Texas leads the pack with 13 active trials investigating treatments such as AG-120, INBRX-109, and Proton Beam Therapy. Following closely behind are Los Angeles, California and New york, New York, both with 11 ongoing studies focusing on therapies like Doxorubicin, LY3410738, and INBRX-109. Chicago, Illinois also shows promise with 10 active trials examining options such as Doxorubicin and LY3410738. Lastly, Boston,Masachusetts offers hope with 8 ongoing studies exploring treatments like LY3410738and AG-120.In these cities across the United States,chondrosarcoma patients have access to cutting-edge clinical trials that may pave the way for improved treatment outcomes.It's important to consult medical professionals for specific recommendations tailored to individual cases.
Which are the top treatments for chondrosarcoma being explored in clinical trials?
Exciting progress is being made in clinical trials for chondrosarcoma, with several top treatments showing promise. AG-120 has emerged as a frontrunner, currently undergoing two active trials and contributing to the total of two all-time chondrosarcoma trials since its listing in 2014. Another contender capturing attention is INBRX-109, involved in two ongoing trials and adding to the tally of two all-time chondrosarcoma studies since 2018. Equally significant is seclidemstat, also participating in two current trials and entering the field in 2018. Lastly, an intriguing newcomer on the scene is CD30 biAb-AATC—a cutting-edge treatment that recently commenced one active trial after its first listing just this year (2022). These advancements mark important strides towards improved therapies for individuals battling chondrosarcoma.
What are the most recent clinical trials for chondrosarcoma?
Recent clinical trials offer hope and potential advancements in the treatment of chondrosarcoma, a rare form of bone cancer. One trial focuses on an experimental therapy called anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC). This innovative approach combines targeted antibodies with activated immune cells to attack cancer cells specifically. Another trial investigates the efficacy of YH001 combined with Envafolimab, aiming to determine the recommended dose for treating chondrosarcoma subtype 1. Additionally, Seclidemstat is being evaluated as a potential therapeutic option for this aggressive tumor type. These studies provide valuable insights into new treatment avenues that may improve outcomes for individuals battling chondrosarcoma.
What chondrosarcoma clinical trials were recently completed?
A recent milestone has been reached in the field of chondrosarcoma research, with the completion of a clinical trial investigating FT-2102. Conducted by Forma Therapeutics, Inc., this trial concluded in November 2018. This significant endeavor contributes valuable insights to our understanding and treatment approaches for chondrosarcoma, highlighting the ongoing efforts to improve outcomes for patients affected by this challenging condition.